Neuropeptides as emerging targets in anorexia and cachexia

Bibliography

• TISDALE MJ: Biology of cachexia. I Nati Cancer Inst. (1997) 89:1763–1773.
   PubMed Web of Science ®Google Scholar
• ••An important review of cachexia.
   Google Scholar
• MOLDAWER LL, COPELAND EM: Proinflammatory cytokines, nutritional support and the cachexia syndrome. Cancer (1997) 79:1828–1839.
   PubMed Web of Science ®Google Scholar
• GRUNFELD C, FEINGOLD KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl. I Med. (1992) 327:329–337.
   PubMed Web of Science ®Google Scholar
• INUI A: Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. (1 9 9 9) 59(18)4493–4501.
   PubMedGoogle Scholar
• BRUERA E: Anorexia, cachexia and nutrition. Br. Med. J. (1997) 315:1219–1222.
   PubMed Web of Science ®Google Scholar
• LARKIN M: Thwarting the dwindling progression of cachexia. Lancet (1998) 351:1336.
   PubMed Web of Science ®Google Scholar
• INUI A: Feeding and body weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. Trends Neurosci. (1999) 22 (2):62–67.
   PubMed Web of Science ®Google Scholar
• INUI A: Transgenic approach to the study of body weight regulation. Pharmacol. Rev. (2000) (In Press).
   PubMedGoogle Scholar
• SCHWARTZ MW, DALLMAN MF, WOODS SC: Hypotha-lamic response to starvation: implications for study of wasting disorders. Am. I Physiol (1995) 269:R949–R957.
   Web of Science ®Google Scholar
• SCHWARTZ MW, SEELEY RJ: Neuroendocrine response to starvation and weight loss. N Engl I Med. (1997) 336:1802–1811.
   PubMed Web of Science ®Google Scholar
• WOODS SC, SEELEY RJ, PORTE JRD, SCHWARTZ MW: Signals that regulate food intake and energy homeostasis. Science (1998) 280:1378–1383.
   PubMed Web of Science ®Google Scholar
• ••An important review of energy homeostasis.
   Google Scholar
• HEINRICHS SC, MENZAGHI F, KOOB GF: Neuropeptide Y-induced feeding and its control. Vitam. Horm. (1998) 54:51–66.
   PubMed Web of Science ®Google Scholar
• •An important review of NPY.
   Google Scholar
• ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372 (6505):425–432.
   PubMed Web of Science ®Google Scholar
• TARTAGLIA LA, DEMBSKI M, WENG X et al.: Identifica-tion and expression cloning of a leptin receptor, OB-R. Cell (1995) 83(7):1263–1271.
   PubMed Web of Science ®Google Scholar
• OGAWA Y, MASUZAKI H, ISSE N et al.: Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats. I Clin. Invest. (1995) 96(3):1647–1652.
   Google Scholar
• LEE GH, PROENCA R, MONTEZ JM et al Abnormal splicing of the leptin receptor in diabetic mice. Nature (1996) 3 79(6566) 632–635
   PubMedGoogle Scholar
• CHEN H, CHARLAT O, TARTAGLIA LA et al: Evidence that the diabetes gene encodes the leptin receptor: identifi-cation of a mutation in the leptin receptor gene in db/db mice. Cell (1996) 84(3):491–495.
   PubMed Web of Science ®Google Scholar
• CHUA SC, JR., CHUNG WK, WU PENG XS et al.: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science (1996) 271(5251)994–996.
   PubMedGoogle Scholar
• SINHA MK, CARO JF: Clinical aspects of leptin. Vitam. Horm. (1998) 54: 1–30.
   Google Scholar
• STEPHENS TW, BASINSKI M, BRISTOW PK et al.: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature (1995) 377(6549):530–532.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, SEELEY RJ, CAMPFIELD LA, BURN P, BASKIN DG: Identification of targets of leptin action in rat hypothalamus. I Clin. Invest. (1996) 98 (5):1101–1106.
   Google Scholar
• AHIMA RS, PRABAKARAN D, MANTZOROS C et al.: Role of leptin in the neuroendocrine response to fasting. Nature (1996) 382(6588):250–252.
   PubMed Web of Science ®Google Scholar
• WANG Q, BING C, AL BARAZANJI K et al.: Interactions between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes (1997) 46 (3):335–341.
   PubMed Web of Science ®Google Scholar
• PLATA SALAMAN CR: Immunoregulators in the nervous system. Neurosci. Biobehav. Rev. (1991) 15:185–215.
   PubMed Web of Science ®Google Scholar
• PLATA SALAMAN CR: Anorexia during acute and chronic disease. Nutrition (1996) 12:67–78.
   PubMed Web of Science ®Google Scholar
• HASLETT PAJ: Anticytokine approaches to the treatment of anorexia and cachexia. Semin. Oncol. (1998) 25 (Suppl. 6):53–57.
   PubMedGoogle Scholar
• MANTOVANI G, MACCIO A, LAI P, MASSA E, GHIANI M, SANTONA MC: Cytokine activity in cancer-related anorexia/cachexia: Role of megastrol acetate and medroxyprogesterone acetate. Semin. Oncol. (1998) 25 (Suppl 6):45–52.
   PubMedGoogle Scholar
• SARRAF P, FREDERICH RC, TURNER EM et al.: Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. I Exp. Med. (1997) 185:171–175.
   PubMed Web of Science ®Google Scholar
• GRUNFELD C, ZHAO C, FULLER J et al.: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J. Clin. Invest. (1996) 97:2152–2157.
   PubMed Web of Science ®Google Scholar
• FINCK BN, KELLEY KW, DANTZER R, JOHNSON RW: In vivo and in vitro evidence for the involvement of tumor necrosis factor-alpha in the induction of leptin by lipopolysaccharide. Endocrinology (1 9 9 8) 139:2278-2283.
   Google Scholar
• FLIER JS, MARATOS FLIER E: Obesity and the hypothalamus: novel peptides for new pathways. Cell (1998) 92:437–440.
   PubMed Web of Science ®Google Scholar
• KALRA SP: Appetite and body weight regulation: is it all in the brain? Neuron (1997) 19:227–230.
   PubMed Web of Science ®Google Scholar
• INUI A: Neuropeptide Y feeding receptors-are multiple subtypes involved? Trends Pharmacol. Sci. (1999) 20:43–46.
   Web of Science ®Google Scholar
• QU D, LUDWIG DS, GAMMELTOFT S: A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature (1996) 380:243–247.
   PubMed Web of Science ®Google Scholar
• SAKURAI T, AMEMIYA A, ISHII M: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G-protein-coupled receptors that regulate feeding behavior. Cell (1998) 92:573–585.
   PubMed Web of Science ®Google Scholar
• ••An important review of leptin.
   Google Scholar
• MORLEY JE: Neuropeptide regulation of appetite and weight. Endo. Rev. (1987) 8:256–287.
   PubMed Web of Science ®Google Scholar
• CHAMBERS J, AMES RS, BERGSMA D et al.: Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature (1999) 400(6740:261–265.
   PubMedGoogle Scholar
• FELLMANN D, BUGNON C, RISOLD PY: Unrelated peptide immunoreactivities coexist in neurons of the rat lateral dorsal hypothalamus: human growth hormone-releasing factor1-37-, salmon melanin-concentrating hormone-and alpha-melanotropin-like substances. Neurosci. Lett. (1987) 74(3)275–280.
   PubMedGoogle Scholar
• SKOFITSCH G, JACOBOWITZ DM, ZAMIR N: Immunohis-tochemical localization of a melanin concentrating hormone-like peptide in the rat brain. Brain Res. Bull. (1985) 15(6):635–649.
   PubMed Web of Science ®Google Scholar
• BLUET PAJOT MT, PRESSE F, VOKO Z et al.:Neuropeptide-E-I antagonizes the action of melanin-concentrating hormone on stress-induced release of adrenocorticotropin in the rat. J. Neuroendo-crinol (1995) 7(4)297–303.
   PubMed Web of Science ®Google Scholar
• SHIMADA M, TRITOS NA, LOWELL BB, FLIER JS, MARATOS FLIER E: Mice lacking melanin-concentrating hormone arehypophagic and lean. Nature (1 9 9 8)396(6712)670–674.
   PubMedGoogle Scholar
• BROBERGER C, DE-LECEA L, SUTCLIFFE JG, HOKFELT T: Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. J. Comp. Neurol (1998) 402 (4):460–474.
   PubMed Web of Science ®Google Scholar
• DATE Y, UETA Y, YAMASHITA H et al.: Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. USA (1999) 96(2):748–753.
   PubMed Web of Science ®Google Scholar
• MARSHALL JF, TEITELBAUM P: Further analysis of sensory inattention following lateral hypothalamic damage in rats. J. Comp. Physiol. Psycho]. (1974) 86(3)375–395.
   PubMed Web of Science ®Google Scholar
• OLTMANS GA, HARVEY JA: Lateral hypothalamic syndrome in rats: a comparison of the behavioral and neurochemical effects of lesions placed in the lateral hypothalamus and nigrostriatal bundle. J. Comp. Physio. Psycho] (1976) 90(10:1051–1062.
   PubMedGoogle Scholar
• KUNII K, YAMANAKA A, NAMBU T et al.: Orexins/hypocretins regulate drinking behaviour. Brain Res. (1999) 842(0:256–261.
   PubMedGoogle Scholar
• TRIVEDI P, YU H, MACNEIL DJ, VAN-DER-PLOEG LH, GUAN XM: Distribution of orexin receptor mRNA in the rat brain. FEBS. Lett. (1998) 438(1-2):71–75.
   PubMed Web of Science ®Google Scholar
• LARHAMMAR D: Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pep] (1996) 62 (1):1–11.
   PubMedGoogle Scholar
• MICHEL MC, BECK SICKINGER A, COX H et al XVI International Union of Pharmacology recommenda-tions for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. (1998) 50(0:143–150.
   PubMedGoogle Scholar
• INUI A, OKITA M, NAKAJIMA M et al.: Neuropeptide regulation of feeding in dogs. Am. J. Physiol (1991) 261:R588–R594.
   Google Scholar
• BLOMQVIST AG, HERZOG H: Y-receptor subtypes-how many more? Trends Neurosci. (1997) 20 (7):294–298.
   Google Scholar
• GEHLERT DR: Multiple receptors for the pancreatic polypeptide (PP-fold) family: physiological implica-tions. Proc. Soc. Exp. Biol. Med. (1998) 218(0:7–22.
   PubMedGoogle Scholar
• WOLDBYE DP, LARSEN PJ: The how and Y of eating. Nature Med. (1998) 4(6):671–672.
   PubMed Web of Science ®Google Scholar
• GERALD C, WALKER MW, CRISCIONE L et al.: A receptor subtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382(6587):168–171.
   PubMed Web of Science ®Google Scholar
• LARSEN PJ, SHEIKH SP, JAKOBSEN CR, SCHWARTZ TW, MIKKELSEN JD: Regional distribution of putative NPY Y1 receptors and neurons expressing Y1 mRNA in forebrain areas of the rat central nervous system. Eur. Neurosci. (1993) 5(12):1622–1637.
   PubMed Web of Science ®Google Scholar
• SCHAFFHAUSER AO, STRICKER KRONGRAD A, BRUNNER L et al: Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides. Diabetes (1997) 46(11):1792–1798.
   PubMed Web of Science ®Google Scholar
• SHUTTER JR, GRAHAM M, KINSEY AC et al.: Hypotha-lamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes. Dev. (1997) 11(5):593–602.
   PubMed Web of Science ®Google Scholar
• OLLMANN MM, WILSON BD, YANG YK et al: Antagonism of central melanocortin receptors in vitro and in vivo byagouti-related protein. Science (1 9 9 7)2 78(5335):135–138.
   Google Scholar
• LU D, WILLARD D, PATEL IR et al.: Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature (1994) 371 (6500):799–802.
   PubMed Web of Science ®Google Scholar
• BULTMAN SJ, MICHAUD EJ, WOYCHIK RP: Molecular characterization of the mouse agouti locus. Cell (1992) 71(7):1195–1204.
   PubMed Web of Science ®Google Scholar
• LEIBEL RL, CHUNG WK, CHUA SC Jr: The molecular genetics of rodent single gene obesities. J. Biol. Chem. (1997) 272(50:31937–31940.
   PubMedGoogle Scholar
• FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395:763–770.
   PubMed Web of Science ®Google Scholar
• FAN W, BOSTON BA, KESTERSON RA, HROBY VJ, Cone RD: Role of melanocortinnergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 385:165–168.
   PubMed Web of Science ®Google Scholar
• CONE RD: The melanocortin receptors: agonists, antagonists, and the hormornal control of pigmenta-tion. Recent Prog. Horm. Res. (1996) 51:287.
   PubMedGoogle Scholar
• GRAHAM M, SHUTTER JR, SARMIENTO U, SAROSI I, STARK KL: Overexpression of Agrt leads to obesity in transgenic mice [letter]. Nature Genet. (1997) 17(3)273–274.
   PubMedGoogle Scholar
• HUSZAR D, LYNCH CA, FAIRCHILD-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88(1):131–141.
   PubMed Web of Science ®Google Scholar
• SAHU A: Evidence suggesting that galanin (GAL), melanin-concentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology (1998) 139(2)795–798.
   PubMed Web of Science ®Google Scholar
• SEELEY RJ, YAGALOFF KA, FISHER SL et al: Melanocortin receptors in leptin effects. Nature (1997) 390(6658)349.
   Google Scholar
• SCHWARTZ MW, SEELEY RJ, WOODS SC et al.: Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes (1997) 46(12):2119–2123.
   PubMed Web of Science ®Google Scholar
• CHEUNG CC, CLIFTON DK, STEINER RA: Proopiomela-nocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology (1997) 138(10)4489–4492.
   PubMed Web of Science ®Google Scholar
• KESTERSON RA, HUSZAR D, LYNCH CA, SIMERLY RB, CONE RD: Induction of neuropeptide Y gene expres-sion in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol. Endocrinol (1997) 11(5):630–637.
   PubMedGoogle Scholar
• DE SOUZA EB: Corticotropin-releasing factor receptors in the rat central nervous system: charac-terization and regional distribution. J. Neurosci. (1987) 7(1):88–100.
   PubMed Web of Science ®Google Scholar
• GRIGORIADIS DE, LOVENBERG TW, CHALMERS DT, LIAW C, DE SOUZE EB: Characterization of corticotropin-releasing factor receptor subtypes. Ann. NY Acad. Sci. (1996) 780:60–80.
   PubMed Web of Science ®Google Scholar
• DIETERICH KD, LEHNERT H, DE SOUZA EB: Corticotropin-releasing factor receptors: an overview. Exp. Clin. Endocrinol Diabetes (1997) 105(2):65–82.
   PubMed Web of Science ®Google Scholar
• •A thorough review of CRF.
   Google Scholar
• OKITA M, INUI A, INOUE T et al.: Effects of corticotropin-releasing factor on feeding and pancre-atic polypeptide response in the dog. I Endocrinol (1998) 156(2):359–364.
   Web of Science ®Google Scholar
• KAIYALA KJ, WOODS SC, SCHWARTZ MW: New model for the regulation of energy balance and adiposity by the central nervous system. Am. J. Clin. Nutr. (1995) 62(5 Suppl):1123S–1134S.
   Google Scholar
• TURNBULL A, RIVIER C: Corticotropin-releaing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc. Soc. Exp. Biol. Med. (1997) 215:1–10.
   PubMed Web of Science ®Google Scholar
• CHEN R, LEWIS KA, PERRIN MH, VALE WW: Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. USA (1 9 9 3) 90(19)8967–8971.
   Google Scholar
• LOVENBERG TW, LIAW CW, GRIGORIADIS DE et al.: Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA (1995) 92(3)836–840.
   PubMed Web of Science ®Google Scholar
• SMAGIN GN, HOWELL LA, RYAN DH, DE SOUZA EB, HARRIS RBS: The role of CRF2 receptors in corticotropin-releasing factor-and urocortin-induced anorexia. NeuroReport (1998) 9:1601–1606.
   PubMed Web of Science ®Google Scholar
• VAUGHAN J, DONALDSON C, BITTENCOUNT J et al.: Characterization of urocortin, a novel mammalian neuropeptide related to fish urotensin and to CRF. Nature (1995) 378:287–292.
   PubMed Web of Science ®Google Scholar
• SPINA M, MERLO PICH E, CHAN RK et al.: Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science (1996) 273(5280:1561–1564.
   PubMedGoogle Scholar
• ASAKAWA A, INUI A, UENO N, MAKINO S, FUJINO MA, KASUGA M: Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastroenter-ology (1999) 116(6):1287–1292.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395:763–770.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM: Positional cloning of the mouse ob gene and its human homologue. Nature (1994) 372:425–432.
   PubMed Web of Science ®Google Scholar
• FLIER JS: What's in a name? In search of leptin's physio-logical role. J. Clin. Endocrinol. Metab. (1998) 83:1407–1413.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, FIGLEWICZ DP, BASKIN DG, WOODS SC, PORTE D, JR: Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. (1992) 13:387–414.
   PubMed Web of Science ®Google Scholar
• CHEN G, KOYAMA K, YUAN X et al.: Disappearance ofbody fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93(25):14795–14799.
   PubMed Web of Science ®Google Scholar
• MUZZIN P, EISENSMITH RC, COPELAND KC, WOO SL: Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93 (25):14804–14808.
   PubMed Web of Science ®Google Scholar
• HALAAS JL, BOOZER C, BLAIR-WEST J, FIDAHUSEIN N, DENTON DA, FRIEDMAN JM: Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc. Natl. Acad Sci. USA (1997) 94(16)8878–8883.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1 9 9 8) 395(6704)763–770.
   PubMedGoogle Scholar
• ZHANG FM, BASINSKI MB, BEALS JM: Crystal structure of the obese protein leptinE-100. Nature (1997)387:206–209.
   PubMed Web of Science ®Google Scholar
• MERCER JG, HOGGARD N, WILLIAMS M, LAWRENCE CB, HANNAH LT, TRAYHURN P: Localization of leptin receptor mRNA and the long form splice variant (013-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS. Lett. (1996) 387(2-3):113–116.
   PubMed Web of Science ®Google Scholar
• JACOB RJ, DZIURA J, MEDWICK MB et al.: The effect ofleptin is enhanced by microinjection into the ventromedial hypothalamus. Diabetes (1 9 9 7) 46:150–152.
   PubMedGoogle Scholar
• SATOH N, OGAWA Y, KATSUURA G et al: The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci. Lett. (1997) 224 (3) :149–152.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA: Cholecystokinin. In: Gut Peptides Biochem-istry and Physiology. Walsh JH. Dockray GJ (Ed.), Raven, New York (1994):175–216.
   Google Scholar
• •A thorough review of CCK.
   Google Scholar
• SAHU A, KALRA SP: Neuropeptidergic regulation of feeding behavior, neuropeptide Y. Trends Endocrinol Metab. (1993) 4:217–224.
   PubMed Web of Science ®Google Scholar
• HIROSUE Y, INUI A, TERANISHI A: Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice. Am. I Physic)]. (1993) 265:R481–R486.
   Google Scholar
• CANTOR P: Cholecystokinin in plasma. Digestion (1989)42(0181–201.
   PubMed Web of Science ®Google Scholar
• LARSSON LI, REHFELD JF: Distribution of gastrin and CCK cells in the rat gastrointestinal tract.Evidence for the occurrence of three distinct cell types storing COOH-terminal gastrin immunoreactivity. Histochem-istry (1978) 58(1-2):23–31.
   PubMedGoogle Scholar
• INNIS RB, SNYDER SH: Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA (1980) 77(10:6917–6921.
   PubMedGoogle Scholar
• MORAN TH, ROBINSON PH, GOLDRICH MS, MCHUGH PR: Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. (1986) 362 (1):175–179.
   PubMed Web of Science ®Google Scholar
• INUI A, INOUE T, SAKATANI N, OYA M, MORIOKA H, BABA S: Proglumide has access to brain and antago-nizes the central satiety effect of cholecystokinin octapeptide in the dog. Brain Res. (1987) 417:355–359.
   PubMed Web of Science ®Google Scholar
• INUI A, OKITA M, INOUE T et al.: Effect of cholecys-tokinin octapeptide analogues on food intake in the dog. Am. I Physic)]. (1989) 257:R746–R751.
   Google Scholar
• GIBBS J, SMITH GP: Effects of brain-gut peptides on satiety. In: Obesity. Bjärntorp P, Brodoff BN (Ed.), JB Lippincott Co., Philadelphia, USA (1992):399–410.
   Google Scholar
• BADO A, LEVASSEUR S, ATTOUB S et al: The stomach is a source of leptin. Nature (1998) 394(6695):790–793.
   PubMed Web of Science ®Google Scholar
• STERNBERG EM: Neural-immune interactions in health and disease. J. Clin. Invest. (1997) 100:2641–2647.
   PubMed Web of Science ®Google Scholar
• LICINIO J, WONG ML: Pathways and mechanisms for cytokine signaling of the central nervous system. Clin. Invest. (1997) 100:2941–2947.
   Google Scholar
• •Provides important evidence for the relationship between cytokines and CNS.
   Google Scholar
• HOPKINS SJ, ROTHWELL NJ: Cytokines and the nervous system: expression and recognition. Trends Neurosci. (1995) 18:83–88.
   PubMed Web of Science ®Google Scholar
• ROTHVVELL NJ, HOPKINS SJ: Cytokines and the nervous system: actions and mechanisms of action. Trends Neurosci. (1995) 18:130–136.
   PubMed Web of Science ®Google Scholar
• GOEHLER LE, BUSCH CR, TARTAGLIA N et al: Blockade of cytokine induced conditioned taste aversion by subdiaphragmatic vagotomy: further evidence for vagal mediation of immune-brain communication. Neurosci. Lett. (1995) 185:163–166.
   PubMed Web of Science ®Google Scholar
• DAUN JM, MCCARTHY DO: The role of cholecystokinin in interleukin-1-induced anorexia. Physiol Behavior (1993) 54:237–241.
   PubMed Web of Science ®Google Scholar
• STANLEY BG, KYRKOULI SE, LAMPERT S, LEIBOWITZ SF: Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides (1986) 7:1189–1192.
   PubMed Web of Science ®Google Scholar
• STANLEY BG: Neuropeptide Y in multiple hypotha-lamic sites controls eating behavior, endocrine, and autonomic systems for body energy balance. In: The Biology of Neuropeptide Y and Related Peptides. Colmers WF, Wahlestedt C (Ed.), Humana Press., Inc., Totowa (1993):457–509.
   Google Scholar
• EGAWA M, YOSHIMATSU H, BRAY G: Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am. I Physiol (1991) 260:R328–R334.
   Google Scholar
• ZARJEVSKI N, CUSIN I, VETTOR R, ROHNER JEANRENAUD F, JEANRENAUD B: Chronic intracerebroventricular neuropeptide Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocri-nology (1993) 133:1753–1758.
   PubMed Web of Science ®Google Scholar
• HEDNER T, SUN X, JUNGGREN IL, PETTERSSON A, EDVINSSON L: Peptides as targets for antihypertensive drug development. I Hypertens. (1992) 10(7):S121–132.
   Google Scholar
• WIELAND HA, ENGEL W, EBERLEIN W, RUDOLF K, DOODS HN: Subtype selectivity of the novel nonpep-tide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. I Pharmacol (1998) 125(3):549–555.
   PubMed Web of Science ®Google Scholar
• RUDOLF K, EBERLEIN W, ENGEL W et al: The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. I Pharmacol (1994) 271 (2-3) :R11–13.
   PubMed Web of Science ®Google Scholar
• CRISCIONE L, RIGOLLIER P, BATZL HARTMANN C et al.: Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. Clin. Invest. (1998) 102(12):2136–2145.
   Google Scholar
• MALMSTROM RE, LUNDBERG JM: Endogenous NPY acting on the Y1 receptor accounts for the long-lasting part of the sympathetic contraction in guinea-pig vena cava: evidence using SR 120107A. Acta. Physic)]. Scand. (1995) 155(3)329–330.
   PubMedGoogle Scholar
• SERRADEIL LE, GAL C, VALETTE G, ROUBY PE et al.: SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS. Lett. (1995) 362 (2):192–196.
   PubMed Web of Science ®Google Scholar
• WEBSTER EL, LEWIS DB, TORPY DJ, ZACHMAN EK, RICE KC, CHROUSOS GP: In vivo and in vitro characteriza-tion of antalarmin, a nonpeptide corticotropin-releasing hormone (CRI) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology (1996) 137(12)5747–5750.
   Google Scholar
• LUNDKVIST J, CHAI Z, TEHERANIAN R et al.: A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits amdolytic-like activity. Eur. I Pharmacol. (1996) 309 (2):195–200.
   PubMed Web of Science ®Google Scholar
• BARAM TZ, CHALMERS DT, CHEN C, KOUTSOUKOS Y, DE SOUZA EB: The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. (1997) 770(1-2):89–95.
   PubMed Web of Science ®Google Scholar
• GOTTOWIK J, GOETSCHY V, HENRIOT S et al.: Labelling of CRF1 and CRF2 receptors using the novel radioligand, [311]-urocortin. Neuropharmacology (1997) 36(10)1439–1446.
   PubMed Web of Science ®Google Scholar
• SCHULZ DW, MANSBACH RS, SPROUSE J et al.: CP-154, 526: a potent and selective nonpeptide antago-nist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. USA (1996) 93(19):10477–10482.
   PubMed Web of Science ®Google Scholar
• SMITH GW, AUBRY JM, DELLU F et al.: Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 20(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• NOZU T, MARTINEZ V, RIVIER J, TACHE Y: Peripheral urocortin delays gastric emptying: role of CRF receptor 2. Am. J. Physiol (1999) 276(4 Pt 1):G867–874.
   Google Scholar
• VALENTINO RJ, WEHBY RG: Corticotropin-releasing factor: evidence for a neurotransmitter role in the locus ceruleus during hemodynamic stress. Neuroen-docrinology (1988) 48(6):674–677.
   PubMed Web of Science ®Google Scholar
• VALENTINO RJ, PAGE ME, CURTIS AL: Activation of noradrenergic locus coeruleus neurons by hemody-namic stress is due to local release of corticotropin-releasing factor. Brain Res. (1991) 555(1):25–34.
   PubMed Web of Science ®Google Scholar
• REVEL L, MENNUNI L, GAROFALO P, MAKOVEC F: CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity. Behav. Pharmacol. (1998) 9(3):183–194.
   PubMed Web of Science ®Google Scholar
• CHANG RS, LOTTI VJ: Biochemical and pharmacol-ogical characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Natl. Acad Sci. USA (1986) 83(13):4923–4926.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C, KISFALVI I, D'AMATO M, VARGA G: Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment. Pharmacol Ther. (1996) 10(3):411–419.
   PubMed Web of Science ®Google Scholar
• FUNAKOSHI A, MIYASAKA K: Effect of a new cholecys-tokinin antagonist (FK 480) on gene expression of cholecystokinin and secretin in rat intestine. J. Castro-enterol. (1994) 29(3):385–387.
   PubMed Web of Science ®Google Scholar
• BALLAZ S, BARBER A, FORTUNO A et al.: Pharma-cological evaluation of IQM-95, 333, a highly selective CCKA receptor antagonist with arudolytic-like activity in animal models. Br. J. Pharmacol. (1997) 121(4)759–767.
   PubMed Web of Science ®Google Scholar
• MAKOVEC F, BANI M, CHISTE R, REVEL L, ROVATI LC, ROVATI LA: Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity. Arzneimittelforschung (1986) 36(1):98–102.
   PubMed Web of Science ®Google Scholar
• SETNIKAR I, BANI M, CEREDA R et al.: Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneimittelforschung (1987) 37(6):703–707.
   PubMed Web of Science ®Google Scholar
• BABER NS, DOURISH CT, HILL DR: The role of CCK caerulein, and CCK antagonists in nociception. Pain (1989) 39(3):307–328.
   PubMed Web of Science ®Google Scholar
• PONCELET M, ARNONE M, HEAULME M et al.: Neurobe-havioural effects of SR 27897, a selective cholecys-tokinin type A (CCK-A) receptor antagonist. Naunyn. Schmiedebergs Arch. Pharmacol. (1993) 348(1):102–107.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI H, YAZAKI N, ENDO T, NAGASAKI M: Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. Eur. Pharmacol. (1996) 304(1-3):147–154.
   PubMed Web of Science ®Google Scholar
• TACHIBANA I, KANAGAWA K, YAMAMOTO Y, OTSUKI M: Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function. J. Pharmacol. Exp. Ther. (1996) 279(3):1404–1412.
   PubMed Web of Science ®Google Scholar
• POWELL KR, BARRETT JE: Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. Neuropeptides (1991) 19 Supp1:75–78.
   PubMedGoogle Scholar
• TRIVEDI BK, PADIA JK, HOLMES A et al.: Second genera-tion `peptoid' CCK-B receptor antagonists: identifica-tion and development of N-(adamantyloxycarbony0-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. I Med. Chem. (1998) 41(1):38–45.
   Web of Science ®Google Scholar
• CRESPI F: The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp. Clin. Pharmacol. (1998) 20(8):679–697.
   PubMedGoogle Scholar
• LAM YK, BOGEN D, CHANG RS et al.: Novel and potent gastrin and brain cholecystokinin antagonists from Streptomyces olivaceus. Taxonomy, fermentation, isolation, chemical conversions, and physico-chemical and biochemical properties. J. Antibiot. Tokyo (1991) 44 (6):613–625.
   PubMed Web of Science ®Google Scholar
• BOCK MG, DIPARDO RM, EVANS BE et al: Benzodi-azepine gastrin and brain cholecystokinin receptor ligands: L-365, 260. J. Med Chem. (1989) 32(0:13–16.
   PubMedGoogle Scholar
• PATEL S, SMITH AJ, CHAPMAN KL et al.: Biological properties of the benzodiazepine amidine derivative L-740, 093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol. Pharmacol. (1994) 46(5):943–948.
   Google Scholar
• RASMUSSEN K, STOCKTON ME, CZACHURA JF, HOWBERT JJ: Cholecystokinin (CCK) and schizo-phrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity. Eur. Pharmacol. (1991) 209(1-2):135–138.
   PubMed Web of Science ®Google Scholar
• HARRO J, ORELAND L, VASAR E, BRADWEJN J: Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradren-ergic denervation. Eur. Neuropsychopharmacol. (1995) 5(4):447–455.
   PubMed Web of Science ®Google Scholar
• HUGHES J, BODEN P, COSTALL B et al: Development of a class of selective cholecystokinin type B receptor antagonists having potent amdolytic activity. Proc. Natl. Acad. Sci. USA (1990) 87(17):6728–6732.
   PubMed Web of Science ®Google Scholar
• HAYWARD NJ, HARDING M, LLOYD SA, MCKNIGHT AT, HUGHES J, WOODRUFF GN: The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat. Br. J. Pharmacol. (1 9 9 1) 104 (4):973–977.
   PubMed Web of Science ®Google Scholar
• HUNTER JC, SUMAN CHAUHAN N, MEECHAM KG et al.: [311]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol. Pharmacol. (1993) 43(4):595–602.
   PubMed Web of Science ®Google Scholar
• BERTRAND P, BOHME GA, DURIEUX C et al.: Pharma-cological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur. I Pharmacol (1994) 262(3):233–245.
   PubMed Web of Science ®Google Scholar
• PENDLEY CE, FITZPATRICK LR, CAPOLINO AJ et al.: RP 73870, a gastrin/cholecystokinin-B receptor antago-nist with potent anti-ulcer activity in the rat. J. Pharmacol. Exp. Ther. (1995) 273(3):1015–1022.
   PubMed Web of Science ®Google Scholar
• HAGISHITA S, MURAKAMI Y, SENO K et al.: Synthesis and pharmacological properties of ureidomethylcarba-moylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509. Bioorg Med. Chem. (1 99 7) 5(8):1695–1714.
   PubMed Web of Science ®Google Scholar
• REVEL L, FERRARI F, MAKOVEC F, ROVATI LC, IMPICCIA-TORE M: Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur. j Pharmacol. (1992) 216(2)217–224.
   Google Scholar
• NISHIDA A, MIYATA K, TSUTSUMI R et al.: Pharma-cological profile of (R)-1-[2, 3-dihydro-1-(2'-methylp he na cyl)-2-ox o-5-p henyl-1 H-1, 4-benzodiazepin-3-y1]-3-(3-methylphenyOurea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. (1994) 269(2)725–731.
   Google Scholar
• BERTRAND P, BOHME A, PIOT 0: RPR101367, a new potent and selective non-peptide CCK B receptor antagonist. Br. J. Pharmacol. (1995) 116:241.
   Google Scholar
• KALINDJIAN SB, BUCK IM, DAVIES JM et al: Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons. J. Med. Chem. (1996) 39(9):1806–1815.
   PubMed Web of Science ®Google Scholar
• LOWE JA, HAGEMEAN DL, DROZDA SE et al.: 5-pheny1-3-ureidobenzapi-2-ones as cholecystokinin-B antago-nists. J. Med. Chem. (1994) 237:3789–3811.
   Google Scholar
• TSUZUKI K, SUNAZUKA T, MARUI S et al.: Motilides, macrolides with gastrointestinal motor stimulating activity. I. 0-substituted and tertiary N-substituted derivatives of 8, 9-anhydroerythromycin A 6, 9-hemiacet al. Chem. Pharm. Bull (Tokyo) (1989) 37(10)2687–2700.
   PubMed Web of Science ®Google Scholar
• ITOH Z, HONDA R, HIWATASHI K et al: Motilin-induced mechanical activity in the canine alimentary tract. Scandj Gastroenterol. (1976) 39:93–110.
   Google Scholar
• •Provides important evidence for the role of motilin in gastro-intestinal motility.
   Google Scholar
• SATOH M, SAKAI T, SANO I et al.: EM574, an erythro-mycin derivative, is a potent motilin receptor agonist in human gastric antrum. J. Pharmacol. Exp. Ther. (1994) 2 71 (1):574–579.
   Google Scholar
• ASAKAWA A, INUI A, MOMOSE K, UENO N, FUJINO MA, KASUGA M: Motilin increases food intake in mice. Peptides (1998) 19(6):987–990.
   PubMed Web of Science ®Google Scholar
• PLATA-SALAMAN CR, BORKOSKI JP: Chemokines/intercrines and central regulation of feeding. Am. J. Physiol. (1994) 266(5 Pt 2):R1711–R1715.
   Google Scholar
• ADAN RAH, GISPEN WH: Brain melanocortin receptors: from cloning to function. Peptides (1997) 18:1279–1287.
   PubMed Web of Science ®Google Scholar
• CATANIA A, LIPTON JM: a-Melanocyte stimulating hormone in the modulation of host reactions. Encocr. Rev. (1993) 14:564–576.
   PubMed Web of Science ®Google Scholar
• UEHARA Y, SHIMIZU H, SATO N, TANAKA Y, SHIMOMURA Y, MORI M: Carboxyl-terminal tripeptide of alpha-melanocyte-stimulating hormone antago-nizes interleukin-l-induced anorexia. Eur. J. Pharmacol. (1992) 220:119–122.
   PubMed Web of Science ®Google Scholar
• HUANG QH, HRUBY VJ, TATRO JB: Role of central melanocortins in endotoxin-induced anorexia. Am. Physiol. (1999) 276(3 Pt 2):R864–R871.
   Google Scholar
• NABEL GJ, GRUNFELD C: Calories lost-another mediator of cancer cachexia? Nature Med. (1996) 2(4)397–398.
   PubMed Web of Science ®Google Scholar
• CERAMI A: Tumor necrosis factor as a mediator of shock, cachexia and inflammation. Blood Puri! (1993) 11 (2):108–117.
   PubMed Web of Science ®Google Scholar
• OLIFF A: The role of tumor necrosis factor (cachectin) in cachexia. Cell (1988) 54(2):141–142.
   PubMed Web of Science ®Google Scholar
• SPIEGELMAN BM, HOTAMISLIGIL GS: Through thick and thin: wasting, obesity, and TNF alpha. Cell (1993) 73 (4):625–627.
   PubMed Web of Science ®Google Scholar
• STRASSMANN G, FONG M, KENNEY JS, JACOB CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. I Clin. Invest. (1992) 89 (5):1681–1684.
   Google Scholar
• FIGUEROA J, VIJAYAGOPAL P, DEBATA C, PRASAD A, PRASAD C: Azaftig, a urinary proteoglycan from a cachectic cancer patient, causes profound weight loss in mice. Life Sci. (1999) 64(15):1339–1347.
   PubMed Web of Science ®Google Scholar
• LAVIANO A, MEQUID MM, YANG ZJ, GLEASON JR, CANGIANO C, FANELLI FR: Cracking the riddle of cancer anorexia. Nutrition (1996) 12:706–710.
   PubMed Web of Science ®Google Scholar
• CONDE GL, RENSHAW D, LIGHTMAN SL, HARBUZ MS: Serotonin depletion does not alter lipopolysaccharide-induced activation of the rat paraventricular nucleus. J. Endocrinol. (1998) 156:245–251.
   PubMed Web of Science ®Google Scholar
• GIETZEN DW, HAMMER VA, BEVERLY JL, ROGERS QR: The role of serotonin (5HT) in feeding responses to amino acids. In: Kynuremine and Serotonin Pathways. Schwarcz R et al. (Eds.), Plenum Press, New York, USA (1990:389–394.
   Google Scholar
• FLETCHER S, BARNES NM: Autoradiographic localiza-tion of the MI-(9-zacopride labelled 5-11T3 receptor in porcine brain. Neurosci. Lett. (1999) 269(2)91–94.
   PubMedGoogle Scholar
• EDELMAN MJ, GANDARA DR, MEYERS FJ et al.: Seroto-nergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer (1999) 86(4)684–688.
   PubMed Web of Science ®Google Scholar
• BRUERA E, MACMILLAN K, KUEHN N, HANSON J, MACDONALD RN: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer (1990) 66(6):1279–1282.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, MICHALAK JC, SCHAID DJ et al.: Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. j Clin. Oncol (1993) 11(4):762–767.
   Web of Science ®Google Scholar
• •Phase III trials of megestrol acetate.
   Google Scholar
• TCHEKMEDYIAN NS, HICKMAN M, SIAU J et al: Megestrol acetate in cancer anorexia and weight loss. Cancer (1992) 69(5):1268–1274.
   PubMed Web of Science ®Google Scholar
• LONNING PE, LIEN EA: Mechanisms of action of endocrine treatment of breast cancer. Grit. Rev. Oncol/Hematol (1995) 21:158–193.
   PubMed Web of Science ®Google Scholar
• BONOMI P, PESSIS D, BUNTING N et al.: Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin. Oncol. (1985) 12(1 Suppl. 1):36–39.
   PubMed Web of Science ®Google Scholar
• MCCARTHY HD, CROWDER RE, DRYDEN S, WILLIAMS G: Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropep-tide Y concentrations. Eur. J. Pharmacol. (1994) 265(1-2):99–102.
   PubMed Web of Science ®Google Scholar
• KAYE WH: Neuropeptide abnormalities in anorexia nervosa. Psychiatry Res. (1996) 62 (0 :65–74.
   PubMedGoogle Scholar
• ROLLA M, ANDREONI A, BELLITTI D, FERDEGHINI M, GHIGO E, MULLER EE: Corticotrophin-releasing hormone does not inhibit growth hormone-releasing hormone-induced release of growth hormone in control subjects but is effective in patients with eating disorders. J. Endocrinol (1994) 140(2):327–332.
   PubMed Web of Science ®Google Scholar
• SIRINATHSINGHJI DJ, REES LH, RIVIER J, VALE W: Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat. Nature (1983) 305(5930232–235.
   Google Scholar
• BRITTON DR, KOOB GF, RIVIER J, VALE W: Intraven-tricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci. (1982) 31 (4):363–367.
   PubMed Web of Science ®Google Scholar
• SUTTON RE, KOOB GF, LE-MOAL M, RIVIER J, VALE W: Corticotropin releasing factor produces behavioural activation in rats. Nature (1982) 297(5864):331–333.
   PubMed Web of Science ®Google Scholar
• GOLD PW, CHROUSOS G, KELLNER C et al: Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am. J. Psychiatry (1984) 141(5):619–627.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB, WIDERLOV E, BISSETTE G et al: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 226(4680):1342–1344.
   PubMed Web of Science ®Google Scholar
• LIEBSCH G, LANDGRAF R, GERSTBERGER R et al.: Chronic infusion of a CR111 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept. (1995) 59(2):229–239.
   PubMedGoogle Scholar
• HEINRICHS SC, LAPSANSKY J, LOVENBERG TW, DE-SOUZA EB, CHALMERS DT: Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. (1997) 71(1):15–21.
   PubMedGoogle Scholar
• MILLS IH, MEDLICOTT L: Anorexia nervosa as a compul-sive behaviour disease. Q. J. Med. (1992) 83 (303):507–522.
   PubMedGoogle Scholar
• KAYE WH, BERRETTINI W, GWIRTSMAN H, GEORGE DT: Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Arch. Gen. Psychiatry (1990) 47:548–556.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO S, INUI A, KIYOTA N et al.: Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Biol. Psychiatry (1997) 41:1068–1070.
   PubMed Web of Science ®Google Scholar
• GERACIOTI TD, JR, LIDDLE RA: Impaired cholecys-tokinin secretion in bulimia nervosa. N Engl J. Med. (1988) 319(10:683–688.
   PubMedGoogle Scholar